Uncemented primary total hip arthroplasty, presentation of pain, and expression of osteonectin.
Osteonectin (ON) is an important matrix glycoprotein highly expressed in bone. In several in vitro and animal model studies, ON was used as indicator of the state of osseointegration of implanted devices. There are, however, no studies on ON expression in the synovial fluid of patients with total hip joint replacement (THJR). The purpose of our study was to determine the ON concentration in synovial fluid from three groups of patients: primary uncemented THJR with hip pain ("pain" group; n = 15) and without pain ("no-pain" group; n = 12), and patients with osteoarthitis scheduled to receive a primary THJR (control group; n = 5). For the prosthesized groups, the statistical nature of the correlation between ON concentration and patient age, in situ life of the THJR, presence of periprosthetic osteolysis, and presence of debris in the synovial fluid was individually investigated. ON concentration was determined using enzyme-linked immunosorbent assay, the presence of periprosthetic osteolysis was established using X-radiography and Engh's criteria, and the presence of debris was determined using digestion and EDX spectroscopy. ON concentration was significantly lower in the "pain" group compared with the "no-pain" one (median values 19.0 and 53.2 ng/mL, respectively). ON concentration in the control group (median value: 16.9 ng/mL) was comparable with that reported in the literature. In the prosthesized groups, ON concentration was not correlated with patient age, in situ life of the prosthesis, presence of periprosthetic osteolysis, or presence of debris in the synovial fluid. Our results suggest that cases of unexplained pain in THJR patients could be treated by paying special attention to the osseointegration status of the implant by using ON concentration as an early indicator of this status.